Association of gene mutations with clinicopathologic features in patients with external auditory canal squamous cell carcinoma

Morita, Shinya; Kano, Satoshi; Hatanaka, Kanako C.; Hatanaka, Yutaka; Suzuki, Takayoshi; Fukuda, Atsushi; Hoshino, Kimiko; Fujiwara, Keishi; Nakamaru, Yuji; Homma, Akihiro

Association of gene mutations with clinicopathologic features in patients with external auditory canal squamous cell carcinoma

Morita, Shinya; Kano, Satoshi; Hatanaka, Kanako C. et al.

International journal of clinical oncology, 2022, 27(9), 1394-1403

Permalink : https://hdl.handle.net/2115/90369

このアイテムのアクセス数:484件（2026-10-08 23:39 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
Int J Clin Oncol_s10147-022-02191-z	pdf	560 KB	1,425
Supplementary Table 1S	xlsx	17.6 KB	125

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/90369
タイトル	Association of gene mutations with clinicopathologic features in patients with external auditory canal squamous cell carcinoma
著者	Morita, Shinya ; Kano, Satoshi ; Hatanaka, Kanako C. ; Hatanaka, Yutaka ; Suzuki, Takayoshi ; Fukuda, Atsushi ; Hoshino, Kimiko ; Fujiwara, Keishi ; Nakamaru, Yuji ; Homma, Akihiro
著者名 Morita, Shinya
e-Rad_Researcher 00374421 著者名 Kano, Satoshi
著者名 Hatanaka, Kanako C.
著者名 Hatanaka, Yutaka
著者名 Suzuki, Takayoshi
著者名 Fukuda, Atsushi
著者名 Hoshino, Kimiko
著者名 Fujiwara, Keishi
e-Rad_Researcher 20344509 著者名 Nakamaru, Yuji
e-Rad_Researcher 30312359 著者名 Homma, Akihiro
言語	英語
キーワード	External auditory canal cancer
	Squamous cell carcinoma
	Next-generation sequencing
	Gene mutations
	Clinicopathologic features
発行日	2022-09-01
出版者	Springer
収録物名	International journal of clinical oncology
巻(号)	27(9)
ページ	1394-1403
抄録	Background External auditory canal squamous cell carcinoma (EACSCC) is a rare form of malignant tumor. Due to the extremely limited understanding of the genomic landscape in EACSCC, the association between gene mutations and clinicopathologic features remains unclear. This study aimed to explore somatic gene mutations associated with the clinicopathological features in patients with EACSCC, and to identify the candidate gene mutations for predicting survival outcome in EACSCC. Methods Twenty-two tissue samples obtained from patients with EACSCC were analyzed for genetic mutations based on targeted next-generation sequencing and genetic expression based on IHC staining to investigate the driver of tumorigenesis and/or the candidates of genes for predicting clinical outcome in EACSCC. Results Gene alterations were most frequently observed in TP53 (59.1%), followed by CREBBP (9.1%). TP53 mutations showed significant correlation with T classification (P = 0.027) and p53 expression phenotype (P < 0.001). The 5-year overall survival (OS) rates for EACSCC patients with TP53 mutations and wild-type TP53 were 45.0% and 75.0%, respectively. Multivariable analysis using the Cox proportional hazards model demonstrated that TP53 mutations were independent predictors of OS rates for EACSCC patients (P = 0.007). Conclusion This study has suggested that TP53 mutations have potential for use as a biomarker for identifying individuals at high risk of developing tumors and for predicting survival outcome in EACSCC. IHC staining for p53 might play a useful role as screening tool for detecting TP53 mutations in patients with EACSCC.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s10147-022-02191-z
PISSN	1341-9625
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1007/s10147-022-02191-z